Oncolytic Virus Cancer Therapy Pipeline Insight, 2021 1
DelveInsight Business Research LLP
DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2021,” report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline,” report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. 

What is Oncolytic Virus Cancer Therapy?

Oncolytic virus (OV) cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses. The therapeutic efficacy of Oncolytic viruses depends on two main modes of action: First, Oncolytic viruses can inhibit protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts; Second, Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigens and secreting cytokines. Oncolytic virus cancer therapies can be used for diagnosis as well treatment of cancer. The anti-tumor efficacies of these OVs have been evaluated in many preclinical and clinical studies as monotherapy and combination therapy.

Which are Oncolytic Virus Cancer Therapy Emerging Drugs?

Oncolytic Virus Cancer Therapy Emerging Drugs are as followed:-

  • CG0070: CG Oncolgy

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure.

  • ONCOS-102: Targovax

ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor. In February 2021, Targovax announced that ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.

For further product details, request Oncolytic Virus Cancer Therapy Emerging Drug report @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

How many major players are working for Oncolytic Virus Cancer Therapy drugs?

There are approx. 45+ key companies which are developing the Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. Phase III include, CG Oncolgy.

Table of Contents 

Introduction

Executive Summary

Oncolytic Virus Cancer Therapy: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration

Oncolytic Virus Cancer Therapy – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Oncolytic Virus Cancer Therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Oncolytic Virus Cancer Therapy Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III) 

  • Comparative Analysis

CG0070: CG Oncolgy

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Pelareorep: Oncolytics Biotech

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I) 

  • Comparative Analysis

ASP-9801: Astellas Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

Research programme: oncolytic vaccinia virus therapies – AstraZeneca/Transgene

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Oncolytic Virus Cancer Therapy Key Companies

Oncolytic Virus Cancer Therapy Key Products

Oncolytic Virus Cancer Therapy- Unmet Needs

Oncolytic Virus Cancer Therapy- Market Drivers and Barriers

Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion

Oncolytic Virus Cancer Therapy Analyst Views

Oncolytic Virus Cancer Therapy Key Companies

Appendix

Request sample report of Oncolytic Virus Cancer Therapy Pipeline Drugs @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/